Group One Trading
CLRB icon

Group One Trading’s Cellectar Biosciences CLRB Stock Holding History

Group One Trading’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70
Closed -$5.25K – 6724
2024
Q2 		$5.25K Sell
70
-160
-70% -$15.4K ﹤0.01% 5930
2024
Q1 		$27.5K Buy
+230
New +$24.9K ﹤0.01% 5182

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading's CLRB Position: Q4 2025 in Review

Group One Trading sold out of Cellectar Biosciences (CLRB) in Q4 2025, closing a stake of 23 shares — an estimated $129 sold.

Group One Trading first reported a position in CLRB in Q1 2024 and held it in 7 quarters. The position peaked at $31.8K in Q1 2024. 20 funds tracked by Wall St. Rank hold CLRB as of Q4 2025.

  • Group One Trading reported no remaining Cellectar Biosciences position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 23 Cellectar Biosciences shares in Q4 2025, an estimated $129.
  • Group One Trading first reported a position in Cellectar Biosciences in Q1 2024 and held it in 7 quarters.
  • Group One Trading's Cellectar Biosciences position peaked at $31.8K in Q1 2024.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.